MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.aohep.2020.09.002

Медицинская библиотека · Annals of hepatology · 2020

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.

Peribañez-Gonzalez Mario, Cheinquer Hugo, Rodrigues Lino, Lima Maria Patelli, Álvares-da-Silva Mário Reis, Madruga José, Parise Edison Roberto, Pessoa Mário Guimarães, Furtado Juvencio, Villanova Marcia, Ferreira Adalgisa, Mazzoleni Felipe, Nascimento Ecio, Silva Giovanni Faria, Fredrick Linda, Krishnan Preethi, Burroughs Margaret, Reuter Tania

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION AND

OBJECTIVES

Glecaprevir/pibrentasvir is a highly effective and well tolerated treatment for hepatitis C infection. Brazilian patients were not included in the original development studies for glecaprevir/pibrentasvir. This study aimed to assess safety and efficacy of glecaprevir/pibrentasvir in treatment-naïve Brazilian adults without cirrhosis or with compensated cirrhosis.

PATIENTS AND

METHODS

EXPEDITION-3 was a Phase 3, open-label, multicenter study in treatment-naïve Brazilian adults with hepatitis C infection genotype 1-6. Patients without cirrhosis (F2 or F3) or with compensated cirrhosis (F4) received 8 or 12 weeks of glecaprevir/pibrentasvir, respectively. The primary efficacy endpoint was the rate of sustained virologic response at post-treatment Week 12. Secondary endpoints were on-treatment virologic failure and relapse rates. Baseline polymorphisms were assessed in NS3 and NS5A. Adverse events and laboratory abnormalities were monitored.

RESULTS

100 patients were enrolled, 75 received 8 weeks of treatment and 25 received 12 weeks; all patients completed treatment. Overall sustained virologic response at post-treatment Week 12 rate was high (98.0%; 98/100; 95% confidence interval: 93.0-99.4) and remained high regardless of baseline viral or host factors, including demographics, hepatitis C virus RNA levels, polymorphisms in NS3 and/or NS5A, genotype, and relevant comorbidities. 55% of patients reported ≥1 adverse event, the most common being headache (18.0%). Four patients reported serious adverse events; none were considered drug related or led to study drug discontinuation. No hepatic decompensations were observed.

CONCLUSIONS

Glecaprevir/pibrentasvir was effective and well tolerated in treatment-naïve Brazilian patients with hepatitis C infection without cirrhosis and with compensated cirrhosis.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03219216.

Для цитирования: Peribañez-Gonzalez Mario, Cheinquer Hugo, Rodrigues Lino, Lima Maria Patelli, Álvares-da-Silva Mário Reis, Madruga José, Parise Edison Roberto, Pessoa Mário Guimarães, Furtado Juvencio, Villanova Marcia, Ferreira Adalgisa, Mazzoleni Felipe, Nascimento Ecio, Silva Giovanni Faria, Fredrick Linda, Krishnan Preethi, Burroughs Margaret, Reuter Tania. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.. Annals of hepatology. 2020. DOI: 10.1016/j.aohep.2020.09.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.